You can seek FDA approval to launch a generic drug before the expiration of APRISO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the APRISO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on APRISO:-

You can seek FDA approval to launch a generic drug before the expiration of ATRIPLA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ATRIPLA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ATRIPLA:-

You can seek FDA approval to launch a generic drug before the expiration of BOSULIF's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BOSULIF's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BOSULIF:-

You can seek FDA approval to launch a generic drug before the expiration of BRILINTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the BRILINTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on BRILINTA:-

You can seek FDA approval to launch a generic drug before the expiration of EMEND's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EMEND's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EMEND:-

You can seek FDA approval to launch a generic drug before the expiration of EMEND's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EMEND's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EMEND:-

You can seek FDA approval to launch a generic drug before the expiration of EPZICOM's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EPZICOM's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EPZICOM:-

You can seek FDA approval to launch a generic drug before the expiration of EVOTAZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the EVOTAZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on EVOTAZ:-

You can seek FDA approval to launch a generic drug before the expiration of FACTIVE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the FACTIVE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on FACTIVE:-

You can seek FDA approval to launch a generic drug before the expiration of GILOTRIF's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GILOTRIF's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GILOTRIF:-

You can seek FDA approval to launch a generic drug before the expiration of GLEEVEC's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the GLEEVEC's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on GLEEVEC:-

You can seek FDA approval to launch a generic drug before the expiration of HEPSERA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the HEPSERA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on HEPSERA:-

You can seek FDA approval to launch a generic drug before the expiration of IXEMPRA KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the IXEMPRA KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on IXEMPRA KIT:-

You can seek FDA approval to launch a generic drug before the expiration of LATUDA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LATUDA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LATUDA:-

You can seek FDA approval to launch a generic drug before the expiration of LETAIRIS's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LETAIRIS's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LETAIRIS:-

You can seek FDA approval to launch a generic drug before the expiration of LEVITRA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LEVITRA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LEVITRA:-

You can seek FDA approval to launch a generic drug before the expiration of LYRICA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LYRICA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LYRICA:-

You can seek FDA approval to launch a generic drug before the expiration of LYRICA CR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the LYRICA CR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on LYRICA CR:-

You can seek FDA approval to launch a generic drug before the expiration of NEXIUM's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NEXIUM's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NEXIUM:-

You can seek FDA approval to launch a generic drug before the expiration of NEXIUM 24HR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NEXIUM 24HR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NEXIUM 24HR:-

You can seek FDA approval to launch a generic drug before the expiration of NOXAFIL's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the NOXAFIL's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on NOXAFIL:-

You can seek FDA approval to launch a generic drug before the expiration of OTEZLA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the OTEZLA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on OTEZLA:-

You can seek FDA approval to launch a generic drug before the expiration of PRANDIN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PRANDIN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PRANDIN:-

You can seek FDA approval to launch a generic drug before the expiration of PROMACTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PROMACTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PROMACTA:-

You can seek FDA approval to launch a generic drug before the expiration of PROMACTA KIT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the PROMACTA KIT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on PROMACTA KIT:-

You can seek FDA approval to launch a generic drug before the expiration of RAPAFLO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the RAPAFLO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on RAPAFLO:-

A supplementary protection certificate (SPC) is a type of intellectual property right granted in the European Union. It provides an extension of the term of protection for a medicinal product that has been authorized for sale in the EU, beyond the 20-year term provided by the basic patent.

The aim of SPCs is to compensate for the time taken to get regulatory approval for a new drug, and to provide an incentive for companies to invest in research and development in the field of medicinal products.

You can seek FDA approval to launch a generic drug before the expiration of RAVICTI's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the RAVICTI's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on RAVICTI:-

You can seek FDA approval to launch a generic drug before the expiration of REYATAZ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the REYATAZ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on REYATAZ:-

You can seek FDA approval to launch a generic drug before the expiration of SENSIPAR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SENSIPAR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SENSIPAR:-

You can seek FDA approval to launch a generic drug before the expiration of SPIRIVA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SPIRIVA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SPIRIVA:-

You can seek FDA approval to launch a generic drug before the expiration of SPIRIVA RESPIMAT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SPIRIVA RESPIMAT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SPIRIVA RESPIMAT:-

You can seek FDA approval to launch a generic drug before the expiration of SUSTIVA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the SUSTIVA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on SUSTIVA:-

You can seek FDA approval to launch a generic drug before the expiration of TARCEVA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TARCEVA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TARCEVA:-

You can seek FDA approval to launch a generic drug before the expiration of TEKTURNA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TEKTURNA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TEKTURNA:-

You can seek FDA approval to launch a generic drug before the expiration of TEKTURNA HCT's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TEKTURNA HCT's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TEKTURNA HCT:-

You can seek FDA approval to launch a generic drug before the expiration of TRICOR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRICOR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRICOR:-

You can seek FDA approval to launch a generic drug before the expiration of TRIUMEQ's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRIUMEQ's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRIUMEQ:-

You can seek FDA approval to launch a generic drug before the expiration of TRIZIVIR's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the TRIZIVIR's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on TRIZIVIR:-

You can seek FDA approval to launch a generic drug before the expiration of VESICARE's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VESICARE's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VESICARE:-

You can seek FDA approval to launch a generic drug before the expiration of VIMOVO's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VIMOVO's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VIMOVO:-

You can seek FDA approval to launch a generic drug before the expiration of VYZULTA's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the VYZULTA's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on VYZULTA:-

You can seek FDA approval to launch a generic drug before the expiration of ZIAGEN's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the ZIAGEN's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Here are the details of the already filed Para IV certificates on ZIAGEN:-